Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject(TM) Compared to...

Wednesday July 23, 4:30 pm ET DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD - News ) announced today the publication of positive findings from studies demonstrating the superior metabolic profile of VIAject™ ultra rapid-acting insulin compared to the rapid-acting analog, Humalog®, and regular human insulin in healthy volunteers and compared to regular human insulin in patients with type 1 diabetes. The articles appear in the current issues of the journals Diabetologia and Journal of Diabetes Science and Technology. In the Phase I glucose clamp study (Steiner et al., Diabetologia, 2008), ten healthy volunteers received subcutaneous injections of VIAject™ ultra rapid-acting insulin, insulin lispro (Humalog®) or regular human insulin on separate days. The study showed that VIAject™ was absorbed and produced its... [read full story]